Ocrevus finally available on NHS
The availability of Ocrevus has been branded a “landmark moment” by the MS Society.
Read More
Tag: ocrelizumab
SMC accepts four medicines for NHS use
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.
Read More
MS Society launches petition against NICE’s rejection of Ocrevus
The MS Society has launched a petition imploring the National Institute for Health and Care Excellence, NHS England and Roche to come to an agreement on NHS availability of Ocrevus for primary progressive multiple sclerosis (PPMS).
Read More
Three cancer treatments approved for use on NHS Scotland
Three treatments have been approved for NHS funding in Scotland, bringing new options for gastroenteropancreatic tumours, lung and kidney cancers, but patients with multiple sclerosis will be unable to access Roche’s Ocrevus following a rejection by the SMC.
Read More
NICE ‘no’ for Roche’s Ocrevus in primary progressive MS
The National Institute for Health and Care Excellence has concluded that Roche’s Ocrevus should not be funded on the NHS for the treatment of primary progressive multiple sclerosis (PPMS) in adults.
Read More
NICE u-turn backs Roche’s Ocrevus for multiple sclerosis
Roche’s Ocrevus has now won NICE backing as a treatment for relapsing–remitting multiple sclerosis in adults, having first been turned down by the cost watchdog.
Read More
NICE ‘no’ for Roche’s Ocrevus
The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s multiple sclerosis therapy Ocrevus.
Read More
EU clears Roche’s Ocrevus for MS
Roche’s Ocrevus has been approved for use in Europe to treat adults with relapsing multiple sclerosis (RMS) and early primary progressive multiple sclerosis (PPMS).
Read More
Ten new medicines leap towards EU approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use has put 10 medicines forward for approval in the region, including new options for multiple sclerosis, eosinophilic esophagitis and eosinophilic asthma.
Read More
US clears new treatments for MS, atopic dermatitis
Roche/Genentech’s Ocrevus has been approved by the US Food and Drug Administration to treat both relapsing and primary progressive forms of multiple sclerosis, while Sanofi’s Dupixent was cleared for certain patients with moderate-to-severe atopic dermatitis.
Read More
Roche unveils more data backing MS drug Ocrevus
Roche has released more data showing that its multiple sclerosis drug Ocrevus works better than Merck’s Rebif against the relapsing form of the disease, and also has potential in controlling the primary progressive type, bringing further hope of the first approved treatment option for this subset of patients.
Read More
Speedy review for Roche/Genentech’s MS drug Ocrevus
US regulators are undertaking a priority review of Roche/Genentech’s experimental multiple sclerosis therapy Ocrevus, which many believe has the potential to transform treatment of the disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
